Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate

Genovese, M. C., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., Valente, R., Nash, P., Simon‐Campos, J. A. +10 more·2011·Arthritis & Rheumatism
DOI 10.1002/art.30463

Cited by (196)

Items 101–196 of 196

  1. Routes of Delivery for Biological Drug Products
    Darrell J. Irvine, Xingfang Su, Brandon Kwong · 2013 · Pharmaceutical Sciences Encyclopedia
  2. A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations
    Alvin F. Wells, Nicole Jodat, Michael H. Schiff · 2014 · Biologics
  3. Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety
    Rossella Reggia, Franco Franceschini, Anǵela Tincani, Ilaria Cavazzana · 2014 · The Journal of Rheumatology
  4. Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders
    Koichi Amano, Tsukasa Matsubara, Takaaki Tanaka, Hiroshi Inoue, Mitsuhiro Iwahashi, Toshihisa Kanamono, Teruaki Nakano, Shoichi Uchimura, Tomomaro Izumihara, Akira Yamazaki et al. · 2015 · Modern Rheumatology
  5. Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients
    M. López-Maraver, Ana Serrano-Combarro, Belén Atienza‐Mateo, N. Del-Val, Ivette Casafont-Sole, Rafael Benito Melero-Gonzalez, Alba Pérez-Linaza, Jerusalem Calvo Gutierrez, Natalia Mena Vázquez, N. Vegas-Revenga et al. · 2024 · Seminars in Arthritis and Rheumatism
  6. New therapeutic approaches in rheumatoid arthritis.
    R. van Vollenhoven · 2016 · Presse medicale
  7. Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open‐Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission
    Joanna Kedra, Philippe Dieudé, Caroline Giboin, Hubert Marotte, Carine Salliot, Thierry Schaeverbeke, Aleth Perdriger, Martin Soubrier, Jacques Morel, Arnaud Constantin et al. · 2023 · Arthritis & Rheumatology
  8. Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives
    Dawn M. Wahezi, Norman T. Ilowite · 2013 · Expert Opinion on Pharmacotherapy
  9. Abatacept Use in Rheumatoid Arthritis: Evidence Review and Recommendations
    Emilio Martín Mola, Alejandro Balsa, Víctor Manuel Martínez Taboada, Raimón Sanmartí, José Luis Marenco, Federico Navarro Sarabia, Juan Jesús Gómez-Reino, José María Álvaro‐Gracia, Jose Andrés Román Ivorra, L. Lojo et al. · 2012 · Reumatología Clínica (English Edition)
  10. Immunogénicité des biomédicaments : quelles conséquences au cours du traitement de la polyarthrite rhumatoïde ?
    Philippe Goupille · 2015 · La Revue de Médecine Interne
  11. Meta‐Analyses on the Effects of Disease‐Modifying Antirheumatic Drugs on the Most Relevant Patient‐Reported Outcome Domains in Rheumatoid Arthritis
    Marijke van den Dikkenberg, Nathalie Luurssen‐Masurel, Tjallingius Martijn Kuijper, Marc R. Kok, Johanna Maria Wilhelmina Hazes, Pascal H P de Jong, Deirisa Lopes Barreto, Angelique E. A. M. Weel · 2022 · Arthritis Care & Research
  12. Immune modulation of rheumatoid arthritis.
    D. Pappas, L. Geraldino-Pardilla, J. Bathon · 2011 · Baillière's Best Practice & Research : Clinical Rheumatology
  13. Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer
    Phyllis Chan, Stephanie N. Liu, Nathalie H. Gosselin, Zacharie Sauvé, Mathilde Marchand, Alyse Lin, Luis A. Herráez-Baranda, James A. Zanghi, Esther Shearer-Kang, Xiaoyan Liu et al. · 2025 · CPT Pharmacometrics & Systems Pharmacology
  14. An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic
    Rishi K Gupta, Muhammad Ruhul Amin Shipa, Su‐Ann Yeoh, Pauline Buck, Michael R. Ehrenstein · 2020 · Lara D. Veeken
  15. Subcutaneous abatacept in rheumatoid arthritis: current update
    Edward Clark Keystone, Abdulaziz Alkhalaf, Mosaab Makkawy · 2015 · Expert Opinion on Biological Therapy
  16. ABATACEPT FOR RHEUMATOID ARTHRITIS: A NOVEL FORMULATION, NEW MECHANISMS, NEW POSSIBILITIES
    Evgeny Lvovich Nasonov · 2015 · Rheumatology Science and Practice
  17. Co-stimulation Therapy in Rheumatoid Arthritis: Today and Tomorrow
    Michael H. Schiff · 2015 · Current Treatment Options in Rheumatology
  18. Abatacept for Treatment of Rheumatoid Arthritis: Special Focus on the Elderly
    Martin Soubrier, Clément Lahaye, Zuzana Tatar · 2018 · Drugs & Aging
  19. Conversion From Intravenous In-Hospital Belatacept Injection to Subcutaneous Abatacept Injection in Kidney Transplant Recipients During the First COVID-19 Stay-at-Home Order in France
    Dominique Bertrand, Melanie Brunel, Ludivine Lebourg, Anne Scemla, Mathilde Lemoine, Lucile Amrouche, Charlotte Laurent, Christophe M. Legendre, Dominique Guerrot, Dany Anglicheau et al. · 2023 · Transplant International
  20. Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins
    Yow‐Ming Wang, Ping Ji, Sudharshan Hariharan, Jie Wang, Ólanrewaju O. Okusanya, Bilal Abuasal, Hao Zhu, Rajanikanth Madabushi, Shiew Mei Huang, Issam Zineh · 2024 · Clinical Pharmacology & Therapeutics
  21. Predicting Human Subcutaneous Bioavailability of Therapeutic Monoclonal Antibodies from Systemic Clearance and Volume of Distribution
    Mikolaj Milewski, Mikhail D. Murashov, Yash Kapoor, Jingtao Zhang, Wei Zhu, Maria A. Cueto, Nicole Buist · 2024 · Molecular Pharmaceutics
  22. Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan
    Hayato Yamazaki, Fumio Hirano, Tsutomu Takeuchi, Koichi Amano, Jun Kikuchi, Mari Kihara, Waka Yokoyama, Takahiko Sugihara, Kenji Nagasaka, Hiroyuki Hagiyama et al. · 2016 · Modern Rheumatology
  23. Analysis of the Immunogenicity from Abatacept‐Treated Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: Findings From Two Phase III Clinical Trials
    Johanna R. Mora, Robert L. Wong, Mehmooda Shaikh, Margarita Askelson · 2021 · ACR Open Rheumatology
  24. Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis
    Wataru Hirose, Masayoshi Harigai, Koichi Amano, Toshihiko Hidaka, Kenji Itoh, Kazutoshi Aoki, Masahiro Nakashima, Hayato Nagasawa, Yukiko Komano, Toshihiro Nanki · 2022 · Rheumatology Advances in Practice
  25. Model‐Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis
    Yash Gandhi, Julie A. Passarell, Amit Roy, Bindu Murthy · 2020 · The Journal of Clinical Pharmacology
  26. Prescribing Patterns of Intravenous Golimumab for Rheumatoid Arthritis
    Brenna L. Brady, Joseph P. Tkacz, Jennifer H. Lofland, Roxanne Meyer, Susan C. Bolge · 2015 · Clinical Therapeutics
  27. Immunogenicity of Biological Agents: Basic Knowledge and Clinical Implications
    Andrea Matucci, Francesca Nencini, Enrico Maggi, Alessandra Vultaggio · 2014 · Florence Research (University of Florence)
  28. Cardiac pathology and modern therapeutic approach in Behçet disease
    Giuseppe Cocco, Paul Jerie · 2013 · Cardiology Journal
  29. Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis
    Q. Y. Su, Jingting Zhang, Hong-Jie Gao, Yan Zhang, Jing Luo, Ting-Yu Cao, Mengyu Yang, Sheng‐Xiao Zhang · 2025 · Expert Opinion on Drug Safety
  30. Advances in pharmacotherapy for immunoinflammatory rheumatic diseases in the 21st century
    Evgeny Lvovich Nasonov · 2025 · Terapevticheskii arkhiv
  31. Experience with subcutaneous abatacept for rheumatoid arthritis: an update for clinicians
    Majed M. Khraishi · 2014 · Therapeutic Advances in Musculoskeletal Disease
  32. Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate
    Maurizio Benucci, Roberto Ravasio, Arianna Damiani · 2017 · ClinicoEconomics and Outcomes Research
  33. Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration
    Michael H. Schiff, Michael E. Weinblatt, Robert M. Valente, Gustavo Citera, Michael A. Maldonado, Elena M. Massarotti, Yusuf Yazıcı, Roy Fleischmann · 2016 · RMD Open
  34. Model‐Based Meta‐Analysis With MonolixSuite : A Tutorial for Longitudinal Categorical and Continuous Data
    Chloe Bracis, Amit Taneja, Yassine Kamal Lyauk, Heather Barcomb, Amparo de la Peña, Géraldine Cellière · 2025 · CPT Pharmacometrics & Systems Pharmacology
  35. Comparison of subcutaneous and intravenous infliximab in patients with inflammatory bowel disease showed no differences in immunogenicity or treatment persistence at 1 year
    Sarah Helen Hancox, Francesco Mordà, Christopher J. Black, Christian P. Selinger · 2024 · Frontline Gastroenterology
  36. [Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain].
    Rafael Ariza Ariza, Anneloes van Walsem, C Canal, Celia Roldán, Lourdes Betegón, Itziar Oyagüez, Katharina Janssen · 2014 · PubMed
  37. Abatacept in the long-term treatment of rheumatoid arthritis
    Meghna Jani, Kimme Leanne Hyrich · 2012 · Expert Review of Clinical Immunology
  38. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)
    Ruediger B. Müeller, Michael Gengenbacher, Symi Richter, Jean Dudler, Burkhard Möller, Johannes von Kempis · 2016 · Arthritis Research & Therapy
  39. Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis
    Philip G. Conaghan, Chadi Rakieh · 2014 · Therapeutics and Clinical Risk Management
  40. T-cell costimulation and other directed therapies
    Ernest Choy · 2015 · Elsevier eBooks
  41. RAISE – Rheumatoid Arthritis Independent Swiss Treatment Expectations and Outcome: results for the abatacept subpopulation
    Jean Dudler, Roland Tuerk, T Handschin, Adrian Forster · 2013 · Swiss Medical Weekly
  42. PHARMACEUTICAL AND CLINICAL CHALLENGES OF BIOLOGICAL MEDICINES: ONGOING HURDLES FROM DRUG DEVELOPMENT TO THERAPEUTIC APPLICATIONS
    SAYON PAUL, AVIK SARKAR · 2024 · Asian Journal of Pharmaceutical and Clinical Research
  43. Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis
    Alexandrina Balanean, Cherrishe Brown‐Bickerstaff, Andrew J. Klink, Vardhaman Patel, Hanke Zheng, Laetitia N’Dri, Keith Wittstock, Bruce A. Feinberg, Mark Chaballa, Vadim Khaychuk et al. · 2024 · Journal of Comparative Effectiveness Research
  44. Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab
    A. Negoescu, A. Östör · 2014 · Rheumatology and Therapy
  45. Optimal search strategies for identifying moderators and predictors of treatment effects in PubMed
    Marcia Tummers, Ralph van Hoorn, Charlotte Levering, Andrew Booth, Gert Jan van der Wilt, Wietske Kievit · 2018 · Health Information & Libraries Journal
  46. Subcutaneous abatacept in rheumatoid arthritis: A real-life experience
    Juan Camilo Sarmiento-Monroy, Luisa Parada-Arias, J. Rodríguez-López, Mónica Rodríguez‐Jiménez, Nicolás Molano‐González, Adriana Rojas‐Villarraga, Rubén D. Mantilla · 2019 · Journal of Translational Autoimmunity
  47. Empfehlungen zum Einsatz von Abatacept bei Patienten mit rheumatoider Arthritis
    Die Kommission Pharmakotherapie der DGRh, Markus Gaubitz, K. Krüger, Johannes‐Peter Haas · 2014 · Zeitschrift für Rheumatologie
  48. What Next after Biologic Therapy Fails in Rheumatoid Arthritis?
    Guro Løvik Goll, Tore Kristian Kvien · 2020 · New England Journal of Medicine
  49. Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials
    Philippe Dieudé, Jeffrey A. Sparks, Aryeh Fischer, Leo Chen, Karissa L. Lozenski, Stephanie Dahan, Mark Chaballa, Wayne A. Little · 2025 · Seminars in Arthritis and Rheumatism
  50. Long-term persistence of biological agents in the treatment of patients with rheumatoid arthritis: a systematic literature review and meta-analysis
    Emilce Edith Schneeberger, María Laura Acosta Felquer, Gustavo Citera, Enrique Roberto Soriano, Eduardo Mysler, Walter Masson, Lorenzo Martín Lobo · 2025 · Clinical Rheumatology
  51. Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis – a systematic evaluation of the literature
    Tran, Caspard, Magrini · 2013 · Open Access Rheumatology Research and Reviews
  52. Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
    Lisa M. Lundquist · 2012 · Open Access Rheumatology Research and Reviews
  53. Small Molecule Inhibitors in Rheumatoid Arthritis
    Eun Bong Lee · 2012 · Journal of Rheumatic Diseases
  54. Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus
    Rieke Alten, Hans‐Peter Tony, Bettina Bannert, Hubert G Nüßlein, C. Rauch, Seán Connolly, Melanie Chartier, Karissa L. Lozenski, Roland Hackl, Adrian Forster et al. · 2023 · Clinical Rheumatology
  55. Long-term persistence of biological agents in the treatment of patients with Rheumatoid Arthritis: a systematic review of the literature
    E. E. Schneeberger, María Laura Acosta Felquer, Gustavo Citera, Enrique Roberto Soriano, Eduardo Mysler · 2020 · Revista Argentina de Reumatología
  56. Non-TNF biologics and their biosimilars in rheumatoid arthritis
    Tsz-Ching Mok, Chi C. Mok · 2024 · Expert Opinion on Biological Therapy
  57. Documento práctico para el uso de abatacept subcutáneo
    Emilio Martín Mola, Alejandro Balsa, Víctor Manuel Martínez Taboada, José Luis Marenco, Federico Navarro Sarabia, Juan Jesús Gómez-Reino, José María Álvaro‐Gracia, Jose Andrés Román Ivorra, L. Lojo, Chamaida Plasencia et al. · 2014 · Reumatología Clínica
  58. Practice Guidelines for the Use of Subcutaneous Abatacept
    Emilio Martín Mola, Alejandro Balsa, Víctor Manuel Martínez Taboada, José Luis Marenco, Federico Navarro Sarabia, Juan Jesús Gómez-Reino, José María Álvaro‐Gracia, Jose Andrés Román Ivorra, L. Lojo, Chamaida Plasencia et al. · 2014 · Reumatología Clínica (English Edition)
  59. Efficacy and safety of infliximab or adalimumab, versus abatacept, in patients with rheumatoid arthritis: ATTEST–AMPLE network randomized trial
    Robin Christensen, Simon Tarp, Daniel E. Furst, Lars Erik Kristensen, Henning Bliddal · 2013 · International Journal of Clinical Rheumatology
  60. Value of immunogenicity in the TNF-α inhibitor treatment of rheumatic diseases
    Н. В. Чичасова · 2015 · Modern Rheumatology Journal
  61. Utilité pratique de la surveillance de l’immunogénicité des anticorps monoclonaux en thérapeutique dans la polyarthrite rhumatoïde
    Philippe Goupille · 2017 · Revue du Rhumatisme Monographies
  62. Economic Benefit of Sponsored Controlled Clinical Trials: The Avoidable Cost in Drugs for the Treatment of Rheumatoid Arthritis
    Federico Liberman, Jorge Federico Elgart, Ingrid Strusberg · 2019 · Value in Health Regional Issues
  63. A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®)
    Soo-Hyun Kim, Siun Kim, Howard Lee · 2020 · Drug Design Development and Therapy
  64. A novel missense variant in CTLA4 associated with immune dysregulation
    Andrew Wong-Pack, Vivian G. Szeto, Kristine Jeganathan, Mihir D. Bhatt, Rae Brager, Jenny Garkaby · 2025 · LymphoSign Journal
  65. Cost–effectiveness of abatacept for moderate-to-severe rheumatoid arthritis
    Nicole Tsao, Kam Shojania, Carlo A. Marra · 2013 · Expert Review of Pharmacoeconomics & Outcomes Research
  66. Efficacy and Safety of Rituximab in Biologic-Naive Patients with Rheumatoid Arthritis vs Anti-Tnf Therapy Failure
    Luis Arturo Gutierrez-Gonzalez, Marco Antonio Rivera Gudiño, Ibell Oropeza Ceija, Marialina Marin Leonet, Zair Tovar Noguera · 2013 · The Open Rheumatology Journal
  67. WITHDRAWN: Abatacept as a first-line biological therapy
    Roberto Felice Caporali, Serena Bugatti, Lorenzo Cavagna, Marco Antivalle, Fabiola Atzeni, Piercarlo Sarzi‐Puttini · 2013 · Autoimmunity Reviews
  68. Biologic modifiers of inflammatory diseases
    Pim Jetanalin, Sang Hyuck Lee, Arthur Kavanaugh · 2013 · Elsevier eBooks
  69. A narrative review on subcutaneous injection components used for alopecia
    Jung‐Hyun Kim · 2022 · Journal of Cosmetic Dermatology
  70. New Biologic Therapies in the Management of Psoriatic Arthritis: An Overview
    Maria Isabel Gomez Coral · 2023 · JOJ Dermatology & Cosmetics
  71. Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort
    Emanuele Molteni, Carmelo Pirone, Fulvia Ceccarelli, Chiara Castellani, Cristiano Alessandri, Manuela Di Franco, Valeria Riccieri, Francesca Romana Spinelli, Roberta Priori, Rossana Scrivo et al. · 2024 · Reumatismo
  72. Abatacept retention and clinical effectiveness in patients with rheumatoid arthritis in a real‐world setting in Taiwan
    Kun‐Hung Chen, Ko‐Jen Li, Yao‐Fan Fang, Song‐Chou Hsieh, Ying‐Chou Chen, Chyou-Shen Lee, Shue‐Fen Luo, Tien‐Tsai Cheng, Wen‐Chan Tsai, Yu‐Chen Lo et al. · 2024 · International Journal of Rheumatic Diseases
  73. Passage du tocilizumab ou de l’abatacept de la forme intraveineuse vers la voie sous-cutanée pendant la pandémie de COVID-19 : expérience française
    Alice Combier, Sarah Wanono, Lucile Poiroux, C. Frantz, Elise Descamps, O. Fogel, Margaux Boisson, Xavier Ayral, C. Bottois, Yannick Allanore et al. · 2021 · Revue du Rhumatisme
  74. Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
    Roberto Felice Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi · 2021 · Global & Regional Health Technology Assessment
  75. Abatacept and Belatacept
    Robert Peach · 2013
  76. European Congress of Rheumatology, Berlin (6-9 June 2012)
    Evgeny Lvovich Nasonov, Lev Nikolayevich Denisov, Vera N. Amirdzhanova · 2012 · Rheumatology Science and Practice
  77. The future of biological agents in the treatment of rheumatoid arthritis
    Charlotte Rawlings, Ernest Choy · 2014 · International Journal of Clinical Rheumatology
  78. Dr. Genovese comments
    Mark C. Genovese · 2015 · The Journal of Rheumatology
  79. Adverse side-effects of biological agents: Hypersensitivity reactions
    Zorica Stojić-Vukanić, Nevena Arsenović-Ranin, Jelena Antić‐Stanković, Marina Milenković · 2014 · Arhiv za farmaciju
  80. Значение иммуногенности при лечении ревматических заболеваний ингибиторами фактора некроза опух о ли α
    Н. В. Чичасова, I. M. Sechenov · 2015
  81. Cell-Targeted Biologics and Emerging Targets
    Peter Charles Taylor · 2016 · Elsevier eBooks
  82. Tolérance et efficacité à 5 ans d’abatacept sous-cutané chez des patients présentant une PR modérée à sévère et une réponse inadéquate au MTX : extension à long terme de l’étude de phase III, randomisée et en double aveugle ACQUIRE
    Patrick Durez, Mark C. Genovese, César Pacheco‐Tena, A. Covarrubias, G. Léon, Eduardo Mysler, M. Keiserman, Robert M. Valente, Peter T. Nash, Jesus Abraham Simón Campos et al. · 2016 · Revue du Rhumatisme
  83. Subcutaneous and intravenous applications of abatacept therapy used in the treatment of rheumatoid arthritis show similar efficacy
    Ahmet Karataş, Burak Öz, Ahmet Yıldırım, Servet Yolbaş, Süleyman Serdar Koca · 2020 · Ulusal Romatoloji Dergisi
  84. Does Abatacept Induce Testicular Toxicity?
    Sultan M. Al-Mogairen · 2020 · Archives of Rheumatology
  85. Zellbasierte Therapeutika in der pädiatrischen Rheumatologie
    Norbert Wagner, Tilmann Kallinich · 2021 · Springer Reference Medizin
  86. Efficacy and safety of immune checkpoint inhibitors and cytokine therapy in autoimmune diseases
    Reyhaneh Sabourian, Seyedeh Zohreh Mirjalili, Nima Rezaei · 2022 · Elsevier eBooks
  87. Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis
    Wataru Hirose, Masayoshi Harigai, Koichi Amano, Toshihiko Hidaka, Kenji Itoh, Kazutoshi Aoki, Masahiro Nakashima, Hayato Nagasawa, Yukiko Komano, Toshihiro Nanki · 2020 · Research Square
  88. Communications posters
    2013 · Revue du Rhumatisme
  89. Zellbasierte Therapeutika in der pädiatrischen Rheumatologie
    Norbert Wagner, Tilmann Kallinich · 2022 · Springer Reference Medizin
  90. Terapias células T alvo (anti-CD80/86)
    Nilton Salles Rosa Neto · 2021 · Revista Paulista de Reumatologia
  91. Imunogenicidade dos fármacos imunobiológicos
    Mônica Simon Prado, Sara de Brito Rocha, Luís Eduardo Coelho Andrade · 2016 · Revista Paulista de Reumatologia
  92. Two-year treatment persistence with subcutaneous abatacept in rheumatoid arthritis: results from the French cohort of the ASCORE study
    René‐Marc Flipo, Arnaud Constantin, Philippe Goupille, Mélanie Chartier, Anaël Ohayon, Xavier Mariette A · 2023 · Clinical and Experimental Rheumatology
  93. APÉNDICE 1: Recomendaciones para el tratamiento de la artritis reumatoidea. Parte 1
    Sociedad Argentina De Reumatología · 2025 · Revista Argentina de Reumatología
  94. Additional file 2 of Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis
    Hirose, Wataru, Masayoshi Harigai, Amano, Koichi, Hidaka, Toshihiko, Itoh, Kenji, Kazutoshi Aoki, Nakashima, Masahiro, Hayato Nagasawa, Yukiko Komano, Toshihiro Nanki · 2021 · Figshare
  95. Agrégation et immunisation contre les protéines thérapeutiques : étude de la maturation des cellules dendritiques et de la réponse lymphocytaire
    Myriam Nabhan · 2019 · theses.fr (ABES)
  96. Immunogenicity of biologics delivered in the subcutaneous space: Delineating the contributing factors
    Vibha Jawa, Sophie Tourdot, Manjunath Shivaraju, Marisa Joubert, Sathy V. Balu‐Iyer, Kari Cox, Ming Cheng, Ying Chen, Masano Huang, Karoline Bechtold Peters et al. · 2026 · Journal of Pharmaceutical Sciences